SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Mathijssen Ron H. J.)
 

Search: WFRF:(Mathijssen Ron H. J.) > (2015-2019) > Impact of Older Age...

  • Crombag, Marie-Rose B S (author)

Impact of Older Age on the Exposure of Paclitaxel : a Population Pharmacokinetic Study.

  • Article/chapterEnglish2019

Publisher, publication year, extent ...

  • 2019-01-07
  • Springer Science and Business Media LLC,2019
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:uu-494347
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-494347URI
  • https://doi.org/10.1007/s11095-018-2563-6DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • PURPOSE: Limited available data suggest that older patients are more prone to develop paclitaxel-induced toxicity than their younger peers. It remains unclear whether this is related to age-dependent pharmacokinetics (PK) of paclitaxel. Primary objective of this study was to determine the influence of older age on the PK of paclitaxel.METHODS: PK data of patients aged ≥70 years who received paclitaxel intravenously at the Netherlands Cancer Institute (NKI) and the Radboud University Medical Center between September 2012 and May 2017 were collected. These prospectively collected data were pooled with previously published databases from multiple clinical trials conducted at the NKI and Erasmus MC Cancer Institute. A previously developed 3-compartment population PK model with saturable distribution and elimination was used to describe paclitaxel plasma concentration-time data. Hereafter, influence of age on paclitaxel PK was assessed in a previously established full covariate model.RESULTS: In total, paclitaxel PK data from 684 patients were available, consisting of 166 patients ≥70 years (24%). Median age of the cohort was 61 years (range 18 to 84 years). The impact of age, either treated as a continuous or dichotomous covariate (<70 versus ≥70 years), on the elimination of paclitaxel was only marginal but statistically significant (both p < 0.001 with no clinically relevant decrease in interindividual variability). For a typical patient, maximal elimination capacity decreased by only 5% for a 10-year increment of age.CONCLUSION: In this extensive multi-center dataset, which included a considerable number of older patients, older age had no clinically relevant impact on paclitaxel PK.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • de Vries Schultink, Aurelia H M (author)
  • Koolen, Stijn L W (author)
  • Wijngaard, Sophie (author)
  • Joerger, Markus (author)
  • Schellens, Jan H M (author)
  • Dorlo, Thomas P CNetherlands Cancer Institute(Swepub:uu)thodo249 (author)
  • van Erp, Nielka P (author)
  • Mathijssen, Ron H J (author)
  • Beijnen, Jos H (author)
  • Huitema, Alwin D R (author)
  • Netherlands Cancer Institute (creator_code:org_t)

Related titles

  • In:Pharmaceutical research: Springer Science and Business Media LLC36:2, s. 33-0724-87411573-904X

Internet link

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view